Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Recipient : Allay Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Bupivacaine
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Recipient : Allay Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Difelikefalin Acetate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : CARA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Product Name : Korsuva
Product Type : Peptide
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Difelikefalin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : CARA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MR13A9
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 14, 2019
Lead Product(s) : MR13A9
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2016
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2011
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DA-9501
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 22, 2011
Lead Product(s) : DA-9501
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
